Increases in extracellular calcium (Ca++) can alter vascular tone, and thus may result in increased blood pressure (Bp) and reduced renal blood flow (RBF). Ca`+ can stimulate prostaglandin E2 (PGE2) and/or prostacyclin (PGI2) release in vitro, which may modulate Ca`+ vascular effects. However, in man, the effect of Ca" on PG release is not known. To study this, 14 volunteers received low-dose (2 mg/kg Ca`+ gluconate) or high-dose (8 mg/ kg) Ca`+ infusions. The low-dose Ca`+ infusion did not alter systemic or renal hemodynamics, but selectively stimulated PGI2, as reflected by the stable metabolite 6-keto-PGFla in urine (159±21-244±30 ng/g creatinine, P < 0.02). The same Caì nfusion given during cyclooxygenase blockade with indomethacin or ibuprofen was not associated with a rise in PGI2 and produced a rise in Bp and fall in RBF. However, sulindac, reported to be a weaker renal PG inhibitor, did not prevent the Ca++-induced PGI2 stimulation (129±33-283±90, P < 0.02), and RBF was maintained despite similar increases in Bp. The high-dose Ca++ infusion produced an increase in mean Bp without a change in cardiac output, and stimulated urinary 6-keto-PGFla to values greater than that produced by the 2-mg/kg Ca++ dose (330±45 vs. 244±30, P < 0.05). In contrast, urinary PGE2 levels did not change. A Ca++ blocker, nifedipine, alone had no effect on Bp or urinary 6-keto-PGFla levels, but completely prevented the Ca++-induced rise in Bp and 6-keto-PGFla excretion (158±30 vs. 182±38, P > 0.2). However, the rise in 6-keto-PGFla was not altered by the a, antagonist prazosin (159±21-258±23, P < 0.02), suggesting that calcium entry and not ao receptor activation mediates Ca`+ pressor and PGI2 stimulatory effects.
1. Abbreviations used in this paper: AVP, arginine vasopressin; Bp, blood pressure; CO, cardiac output; GC, gas chromatography; HR, heart rate; MAP, mean arterial pressure; PAH, para-aminohippurate; PM, prostaglandin(s); PGB2, PGD2, PGE,, PGFxa, and PGF2, prostaglandins B2, D2, El, E2, Fa, and F2; PGI2, prostacyclin; RBF, renal blood flow.
Methods
Subjects. 14 healthy volunteers were studied at the LAC/USC Clinical Research Center after 5 d equilibration on a 80-meq Na+, 60-meq K+ diet. All patients gave informed consent and the protocol was approved by our Internal Review Board. Their ages ranged from 20 to 46 . Eight men and six women were studied. All protocols were performed in the afternoon while the subjects were supine to minimize the effects ofposture and diurnal variation (19) .
Effect ofcalcium infusion on systemic and renal hemodynamics. To assess the effect of calcium on the systemic and renal circulation, lowand high-dose calcium infusions were administered over 3 h via constant intravenous infusion (IMED Pump; IMED Corp., San Diego, CA) at 2 mg/kg (n = 14) , and 8 mg/kg calcium gluconate (n = 8). Bp and pulse rate were measured before and every 30 min during infusion using an automated Bp monitoring system (Dinamap Critikon, Inc., Dublin, CA). Cardiac output (CO) was determined noninvasively via a doppler computer technique (20) during some of the low-and high-dose calcium infusions. This doppler method has been validated via comparison with standard thermodilution methods. RBF was measured using para-aminohippurate (PAH) clearance normalized to 1.73 m2 body surface area.
PAH was given at a loading dose of 4 mg/kg and then maintained at a constant infusion. Four baseline plasma samples for PAH were obtained at 5-min intervals after a 2-h equilibration period. Plasma was subsequently obtained at 30-min intervals during the calcium infusions. PAH was measured via a standard spectrophotometric method (21) . RBF was calculated as: (effective renal plasma flow)/! -hematocrit). Serum was obtained for total and ionized calcium before and at hourly intervals during infusions (22) .
Effect of PG inhibition on systemic and renal hemodynamics. To evaluate the role of vasodilatory PG in the control of systemic and renal vascular tone during mild and moderate hypercalcemia, cyclooxygenase inhibitors, indomethacin (50 mg) (Indocin; Merck Sharpe & Dohme, West Point, PA) or ibuprofen (600 mg) (Motrin; Upjohn Co., Kalamazoo, MI) were administered orally every 8 h for 2 d before the low-dose calcium infusions (n = 14). Another cyclooxygenase inhibitor, sulindac (200 mg) (Clinoril; Merck Sharp & Dohme), was also given orally twice a day for 3 d to some subjects (n = 7) before the low-dose calcium infusions.
Effect ofcalcium infusions on urinary PG excretion. To assess basal urinary PG levels, 3-h urines (1300-1600 h) were collected on two separate days during intake of 150 ml of water orally or dextrose in water intravenous infusions. The dose effect of calcium on urinary PG excretion was assessed by collecting 3-h urines during both low-(n = 14) and high (n = 8)-dose calcium infusions. Urine was collected in glass bottles, the volume measured, and aliquots were immediately frozen at -30"C for PGE2 and 6-keto-PGFa assay. Urine samples were also analyzed for sodium, potassium, and creatinine by standard methods.
Effect of calcium channel blockade on calcium-induced Bp and PG changes. Nifedipine (Procardia; Pfizer Inc., New York, NY), a slow calcium channel antagonist (23) , was given at a dosage of 20 mg sublingually 30 min before the high-dose calcium infusion (n = 8). The contents of two standard 10-mg nifedipine capsules were punctured and contents placed sublingually. 3-h urines were collected during calcium blockade alone and, on separate days, with the combination of the calcium antagonist and high calcium infusion.
Role ofalpha adrenergic activation in calcium-induced hemodynamic and PG changes. Evidence from our lab suggests that catecholamines via aI activation stimulate renal PGE2 and PGI2 in man (18) ; therefore, the effect of a, adrenergic blockade on calcium-induced hemodynamic and PG alterations was evaluated. The selective aI adrenergic antagonist prazosin (5 mg) (24) (Minipress; Pfizer Inc.) was given orally 1 h before the high calcium infusions (n = 6). This dosage was previously shown to completely block the pressor and PG12 stimulatory effects of norepinephrine infusion (18) . Systemic Bp and pulse rate were determined before prazosin administration and at 30-min intervals thereafter until completion of calcium infusion.
Radioimmunoassay (RIA) ofPGE2 and 6-keto-PGFa in urine. PGE2 was measured by a previously described method (25) using specific antisera raised in our lab, ethyl acetate extraction, and LH-20 Sephadex chromatography. Antibody cross-reactivity is PGE2, 100%, PGD2, 4%, PGFa, 1%, and 6-keto-PGF,a, PGB2, 13,14-dihydro PGE2, and 13,14-dihydro-I5-keto-PGE2, all <0.1 %. Tracer recovery averages 65%, interassay variation 10%, and water blanks carried through the entire method average 3 pg. The sensitivity is 10 pg/sample and 50% displacement occurs at 30 pg. RIA validation procedures included assay of serially diluted urine (r = 0.94) and comparison with results using the PGE2 antisera from the Institute Pasteur, Paris, France. Comparison revealed a correlation (r = 0.98) with slope of 0.93 (25) .
6-keto-PGF,a was also measured via our published RIA (26 . This system completely separates the 2,3-dinor 6-ketoPGFa metabolite. Antisera was generated in our lab in rabbits by injection of 6-keto-PGFa linked to bovine thyroglobulin using the carbiodiimide reaction in a manner described previously for PGE2 (25 For increased sensitivity, a negative ion chemical ionization procedure was utilized using a Finnigan 3200 GC/mass spectrometer modified for negative ion capabilities (28) . The methoxine-pentafluorobenzyl-trimethyl silyl derivative of 6-keto-PGFa was prepared using the method of Blair (29) . For (Table II) . However, urinary sodium excretion increased (10.4±3.4-21.9±7.8 meq/liter, P < 0.05).
In marked contrast to the lack of hemodynamic effects of this calcium infusion, the same dose of calcium during cyclooxygenase inhibition produced a significant increase in systemic and renal vascular tone (Fig. 1) . The calcium infusion with in- Fig. 2 . The 2-mg/kg calcium dose significantly increased urinary 6-keto-PGFja release (159±21-244±30 ng/g creatinine, P < 0.02). In contrast, urinary PGE2 excretion decreased. Indomethacin administration completely prevented the calciuminduced rise in 6-keto-PGFa excretion and resulted in levels below the control (102±18 ng/g creatinine). However, sulindac did not alter basal 6-keto-PGFIa (130±33 vs. 159±21, P > 0. 3) or the calcium-induced stimulation of PGI2 (129±33-283±90, P < 0.02), Fig. 3 .
Effect ofhigh-dose calcium infusion on Bp and vasodilatory PG release. The 8-mg/kg calcium infusion increased MAP (87±3-108±4 mmHg, P < 0.01) and total serum calcium (Table II) . Fig. 4 shows the effects ofthe high-dose calcium infusion on urinary PG excretion. PGE2 levels were not altered by the calcium infusion. In contrast, urinary 6-keto-PGFIa excretion was markedly stimulated and levels were greater than that produced by the low calcium infusion (330±45 vs. 244±30 ng/g creatinine, P < 0.05), suggesting a dose-response effect. The subsequent studies were designed to investigate the mechanism of this calcium-induced stimulation of PGI2.
Effect of calcium channel inhibition and alpha adrenergic blockade on calcium-mediated PGI2 release. Nifedipine completely prevented the rise in MAP produced by the high calcium infusion (87±2 vs. 82±2 mmHg, P = NS). The high-dose calcium infusion increased urinary Na+ and volume, but these changes were significantly blocked by nifedipine (Table II) . No changes in urinary K+ or creatinine were observed during these maneuvers. The calcium blocker prevented the calcium-induced rise in 6-keto-PGF~a and produced levels not significantly different than control (170±24 vs. 210±46 ng/g creatinine) (Fig. 5) . Nifedipine given alone on a separate day to five subjects did not alter basal MAP (82±4 mmHg) or 6-keto-PGF~a excretion (158±30 vs. 182±38).
Prazosin given before the calcium infusion resulted in urinary Na+, K+, creatinine, and volume that were similar to levels obtained during calcium channel blockade with nifedipine (Table   BP   Mean II). However, prazosin did not prevent the pressor effect of the calcium infusion (88±3-102±4 mmHg, P < 0.02), and did not alter the high calcium-induced rise in 6-keto-PGFa (159±21-258±23, P < 0.02) (Fig. 5 (1-4, 6-8, 10 ). The mechanisms of calciuminduced vascular effects are complex, since calcium can directly produce vascular smooth muscle constriction (9) or mediate the pressor actions of AVP and angiotensin 11 (5, 39) . Other studies suggest a major role for catecholamines since calcium can stimulate norepinephrine release and mediate aI adrenergic receptor activity (4, (40) (41) (42) .
The present results indicate that PG12 is a potent modulator of the systemic and renal vascular actions of calcium. The lowdose calcium infusion given alone did not alter systemic or renal vascular hemodynamics. In contrast, the same calcium infusion given during indomethacin or ibuprofen administration pro- duced a significant increase in Bp and reduction in RBF. Both cyclooxygenase inhibitors totally prevented the calcium induced rise in 6-keto-PGFla, suggesting that PGI2 attenuates the vasoconstrictive effects of calcium. Sulindac has been reported to differ from other cyclooxygenase inhibitors by sparing renal, but inhibiting systemic PG, as reflected by a lack of effect on urinary 6-keto-PGFIa and PGE2 excretion, while lowering systemic PG, as reflected by reduced platelet thromboxane formation (43, 44). However, a recent study in healthy men showed that although basal PGE2 or 6-keto-PGFIa were not altered, furosemide-stimulated PGE2, but not 6-keto-PGFla release, was reduced by sulindac (45) . In addition, other evidence in dogs indicates that the active sulfide form of sulindac when delivered in high concentrations into the renal artery inhibits renal PG production (46) . Therefore, sulindac may partially spare renal PG synthesis due to the reduced levels of active drug that reach the site of renal PG synthesis.
In our study, the results obtained with sulindac were different than with indomethacin or ibuprofen. The infusion of calcium with sulindac did not change RBF despite similar rises in systemic Bp obtained with the other cyclooxygenase inhibitors. In addition, sulindac did not alter either basal or calcium-stimulated levels of urinary 6-keto-PGF1a. These results suggest that sulindac may partially spare renal PGI2 production, and that urinary 6-keto-PGF~a primarily reflects renal PG12 synthesis, a conclusion that is consistent with reports by others (47, 48). The low-dose calcium infusion produced no rise in total calcium and only minimal increases in ionized calcium concentration. However, even this slight calcium increase stimulated PGI2 synthesis, as reflected by an increase in 6-keto-PGFla excretion. This suggests that PGI2 production is very sensitive to even small changes in extracellular calcium concentration.
Previous evidence in vitro suggests that calcium plays a key role in PG biosynthesis. The divalent cation ionophore A23 187 in the presence of calcium stimulates PGE2 synthesis in renal medullary tissue (16) . More recent evidence indicates that the mechanism of calcium-induced PGE2 synthesis is via phospholipase A2 activation through a calmodulin-dependent mechanism (49, 50) . A23 187 in the presence ofcalcium also stimulates PGI2 synthesis in endothelial cells and vascular smooth muscle in culture (17, 51, 52) .
The source of the calcium needed for vasodilatory PG biosynthesis is not known. However, recent evidence indicates that PGI2 and PGE2 may respond to different cellular pools of calcium. Extracellular calcium is particularly important for PGI2 production in vascular tissue. Increases in extracellular calcium directly stimulates PGI2 synthesis in endothelial cells through a mechanism involving calcium entry (53) . The resulting increase in intracellular calcium activates phospholipase A2 via calmodulin. In contrast, other evidence suggests a key role for intracellular calcium for PGE2 release in renal tissue. The ionophore A23 187-mediated PGE2 release is via an increase in intracellular calcium, since changes in extracellular calcium concentration alone do not alter PGE2 release in renal medullary tissue (16, 54) . In cultured medullary collecting tubules, basal PGE2 synthesis requires the presence ofextracellular calcium, but increasing extracellular calcium from 1.0 to 4.0 mM does not further alter PGE2 release (54, 55) . Therefore, changes in extracellular calcium in vivo may selectively alter renal PGI2 synthesis.
The higher dose calcium infusion produced marked hypercalcemia and a clear pressor response. The mechanism of the Bp increase was through a change in peripheral vascular resistance, since CO did not increase. Some studies suggest that calcium can stimulate catecholamine release, which can then produce pressor effects through a, receptor activation (40, 42). To evaluate this potential interaction, the selective a I antagonist prazosin was administered before some high-dose calcium infusions. The results ofthese studies suggest that the pressor action of increased extracellular calcium is not secondary to catecholamine release and a, adrenergic activation, since prazosin did not alter the pressor response. In contrast, nifedipine completely prevented the calcium-induced Bp increase, suggesting that direct calcium entry is a major mechanism of altered vasomotor tone.
In comparison with the low dose ofcalcium, the higher dose infusion produced a greater rise in urinary 6-keto-PGFa excretion. These results suggest that the calcium stimulation of PGI2 release is dose related.
In addition to its pressor actions, norepinephrine stimulates PGI2 synthesis in vitro and in man via a, adrenergic receptor activation (18, 36) . We therefore evaluated the effect ofprazosin on the calcium-induced urinary 6-keto-PGFa increase. Prazosin did not alter the calcium stimulated of PGI2 excretion, suggesting that this response was not via a, receptor activation. The dosage of prazosin used was previously shown to completely prevent norepinephrine-induced pressor and PGI2 stimulatory effects (18) . Therefore, if the calcium effect was secondary to catecholamine release, it would have been blocked by prazosin.
Nifedipine given alone did not alter urinary 6-keto-PGFa excretion. However, the calcium antagonist markedly blunted the calcium-induced PGI2 release. These results indicate that increasing extracellular calcium concentration stimulates PGI2 release through a mechanism involving calcium entry that is sensitive to calcium antagonists. This is the first evidence in man indicating the critical role of extracellular calcium and its entry for PGI2 synthesis.
The low and higher dose calcium infusions failed to stimulate urinary PGE2 excretion despite marked increases in 6-ketoPGF1a. The precise explanation for this selective action of extracellular calcium to stimulate only PGI2 is not totally clear from this study. One explanation is that PGE2 synthesis may be less sensitive to acute changes in extracellular calcium (54, 55) . In addition, recent evidence in vitro suggests that PGE2 synthesis produced by hormones such as angiotensin II is linked to specific pools of hormonally sensitive calcium that activate phospholipase A2 (56) . Other reports in the isolated rat kidney indicate that omission of calcium or addition of calcium blockers to the perfusion medium, which attenuate the effect of AVP to produce renal vasoconstriction, fail to alter the increase in renal PG elicited by the peptide (57) . This evidence suggests that AVP-induced renal PG synthesis does not require extracellular calcium. Therefore, the selectivity in renal PG synthesis can be due to different local cellular responses, depending upon the pool of calcium involved in phospholipase A2 activation and PG synthesis. Alternatively, the phospholipases may reside at different subcellular sites, making them more or less responsive to hormonal and/or calcium effects. The present results suggest that the arachidonic acid released in response to changes in extracellular calcium is primarily converted into PGI2, resulting in unaltered or reduced levels of PGE2.
The measurement of another PGI2 metabolite in urine, 2,3 dinor 6-keto-PGFa has been reported to represent an index of systemic vascular PGI2 production (58) . Although an additional study measuring the dinor metabolite could further test our contention that Ca++ stimulates both renal and extrarenal PGI2, we were unable to use this technique in the current investigation.
Since urinary 6-keto-PGF~a primarily reflects renal PGI2 production, our conclusion that Ca++ stimulates renal and extrarenal PG12 synthesis is based upon indirect evidence. We have reviewed the extensive literature showing in vitro that Ca++ alters systemic vascular tone and PG12 synthesis. In addition, the current results reveal marked changes in systemic and renal hemodynamics during the low-dose Ca++ infusion, with general PG inhibition and only systemic changes with the more selective extrarenal cyclooxygenase inhibitors.
In summary, this study indicates a new vascular regulatory system in which PGI2 plays a key role in modulating the systemic and renal vascular actions of calcium. PG12 synthesis is highly sensitive to changes in extracellular calcium and variations in calcium entry that provide support for its physiologic role in man.
